☰

Henning Lauterbach - Publications

Affiliations: 
2005-2007 Scripps Research Institute, La Jolla, La Jolla, CA, United States 
Tree Info Grants Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Purde MT, Cupovic J, Palmowski YA, Makky A, Schmidt S, Rochwarger A, Hartmann F, Stemeseder F, Lercher A, Abdou MT, Bomze D, Besse L, Berner F, Tüting T, Hölzel M, ... ... Lauterbach H, et al. A replicating LCMV-based vaccine for the treatment of solid tumors. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 38058126 DOI: 10.1016/j.ymthe.2023.11.026  0.438
2023 Boopathy AV, Sharma B, Nekkalapudi A, Wimmer R, Gamez-Guerrero M, Suthram S, Truong H, Lee J, Li J, Martin R, Blair W, Geleziunas R, Orlinger K, Ahmadi-Erber S, Lauterbach H, et al. Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys. Npj Vaccines. 8: 175. PMID 37945621 DOI: 10.1038/s41541-023-00768-x  0.36
2023 Schmidt S, Mengistu M, Daffis S, Ahmadi-Erber S, Deutschmann D, Grigoriev T, Chu R, Leung C, Tomkinson A, Uddin MN, Moshkani S, Robek MD, Perry J, Lauterbach H, Orlinger K, et al. Alternating arenavirus vector immunization generates robust polyfunctional genotype cross-reactive HBV-specific CD8 T cell responses and high anti-HBs titers. The Journal of Infectious Diseases. PMID 37602681 DOI: 10.1093/infdis/jiad340  0.442
2023 Hinterberger M, Endt K, Bathke B, Habjan M, Heiseke A, Schweneker M, Von Rohrscheidt J, Atay C, Chaplin P, Kalla M, Hausmann J, Schmittwolf C, Lauterbach H, Volkmann A, Hochrein H, et al. Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication. Scientific Reports. 13: 5162. PMID 36997583 DOI: 10.1038/s41598-023-32060-2  0.43
2021 Lauterbach H, Schmidt S, Katchar K, Qing X, Iacobucci C, Hwang A, Schlienger K, Berka U, Raguz J, Ahmadi-Erber S, Schippers T, Stemeseder F, Pinschewer DD, Matushansky I, Orlinger KK. Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform. Frontiers in Oncology. 11: 732166. PMID 34722273 DOI: 10.3389/fonc.2021.732166  0.448
2021 Stutte S, Ruf J, Kugler I, Ishikawa-Ankerhold H, Parzefall A, Marconi P, Maeda T, Kaisho T, Krug A, Popper B, Lauterbach H, Colonna M, von Andrian U, Brocker T. Type I interferon mediated induction of somatostatin leads to suppression of ghrelin and appetite thereby promoting viral immunity in mice. Brain, Behavior, and Immunity. PMID 33895286 DOI: 10.1016/j.bbi.2021.04.018  0.489
2021 Hinterberger M, Giessel R, Fiore G, Graebnitz F, Bathke B, Wennier S, Chaplin P, Melero I, Suter M, Lauterbach H, Berraondo P, Hochrein H, Medina-Echeverz J. Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory. Journal For Immunotherapy of Cancer. 9. PMID 33579736 DOI: 10.1136/jitc-2020-001586  0.342
2020 Schmidt S, Bonilla WV, Reiter A, Stemeseder F, Kleissner T, Oeler D, Berka U, El-Gazzar A, Kiefmann B, Schulha SC, Raguz J, Habbeddine M, Scheinost M, Qing X, Lauterbach H, et al. Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer. Oncoimmunology. 9: 1809960. PMID 33457095 DOI: 10.1080/2162402X.2020.1809960  0.341
2020 Raguz J, Schmidt S, Kleisner T, Zerbs M, Bekic G, Feher S, Oeler D, Stemeseder F, Berka U, Kiefmann B, Schulha S, Matushansky I, Lauterbach H, Orlinger K. Abstract 4058: TheraT - a highly versatile arenavirus based vector platform for intravenous and intratumoral cancer immunotherapy Cancer Research. 80: 4058-4058. DOI: 10.1158/1538-7445.Am2020-4058  0.469
2020 Hinterberger M, Medina-Echeverz J, Testori M, Geiger M, Giessel R, Bathke B, Kassub R, Gräbnitz F, Fiore G, Wennier S, Chaplin P, Suter M, Hochrein H, Lauterbach H. P04.02 A novel cancer immunotherapy combines rMVA-CD40L with tumor targeting antibodies Journal For Immunotherapy of Cancer. 8: A37.1-A37. DOI: 10.1136/JITC-2020-ITOC7.71  0.384
2020 Schmidt S, Bonilla WV, Reiter A, Stemeseder F, Kleissner T, Oeler D, Berka U, El-Gazzar A, Kiefmann B, Schulha SC, Raguz J, Habbeddine M, Scheinost M, Qing X, Lauterbach H, et al. Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer Oncoimmunology. 9: 1809960. DOI: 10.1080/2162402X.2020.1809960  0.306
2019 Medina-Echeverz J, Hinterberger M, Testori M, Geiger M, Giessel R, Bathke B, Kassub R, Gräbnitz F, Fiore G, Wennier ST, Chaplin P, Suter M, Hochrein H, Lauterbach H. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies. Nature Communications. 10: 5041. PMID 31695037 DOI: 10.1038/S41467-019-12998-6  0.494
2019 Medina-Echeverz J, Hinterberger M, Giessel R, Bathke B, Kassub R, Fiore G, Chaplin P, Hochrein H, Lauterbach H. Abstract 1468: Synergistic cancer immunotherapy combination of MVA-CD40L with tumor targeting antibodies or checkpoint blockade to achieve strong antitumor immune responses against large, established tumors Cancer Research. 79: 1468-1468. DOI: 10.1158/1538-7445.Am2019-1468  0.473
2018 Bathke B, Pätzold J, Kassub R, Giessel R, Lämmermann K, Hinterberger M, Brinkmann K, Chaplin P, Suter M, Hochrein H, Lauterbach H. CD70 encoded by modified vaccinia virus Ankara enhances CD8 T-cell-dependent protective immunity in MHC class II-deficient mice. Immunology. 154: 285-297. PMID 29281850 DOI: 10.1111/Imm.12884  0.501
2018 Medina-Echeverz J, Hinterberger M, Testori M, Geiger M, Giessel R, Chaplin P, Hochrein H, Lauterbach H. Abstract 727: A novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors Immunology. 78: 727-727. DOI: 10.1158/1538-7445.Am2018-727  0.532
2018 Medina J, Hinterberger M, Testori M, Geiger M, Giessel R, Chaplin P, Hochrein H, Lauterbach H. A novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors Annals of Oncology. 29: iii10. DOI: 10.1093/annonc/mdy047.001  0.338
2018 Medina J, Hinterberger M, Testori M, Geiger M, Giessel R, Bathke B, Kassub R, Graebnitz F, Fiore G, Chaplin P, Hochrein H, Lauterbach H. A novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors European Journal of Cancer. 92: S24. DOI: 10.1093/Annonc/Mdy047.001  0.42
2017 Sanos SL, Kassub R, Testori M, Geiger M, Pätzold J, Giessel R, Knallinger J, Bathke B, Gräbnitz F, Brinkmann K, Chaplin P, Suter M, Hochrein H, Lauterbach H. NLRC4 Inflammasome-Driven Immunogenicity of a Recombinant MVA Mucosal Vaccine Encoding Flagellin. Frontiers in Immunology. 8: 1988. PMID 29416534 DOI: 10.3389/Fimmu.2017.01988  0.493
2017 Schweneker M, Laimbacher AS, Zimmer G, Wagner S, Schraner EM, Wolferstätter M, Klingenberg M, Dirmeier U, Steigerwald R, Lauterbach H, Hochrein H, Chaplin P, Suter M, Hausmann J. Recombinant modified vaccinia virus Ankara generating Ebola virus-like particles. Journal of Virology. PMID 28331098 DOI: 10.1128/Jvi.00343-17  0.45
2015 Wolferstätter M, Schweneker M, Späth M, Lukassen S, Klingenberg M, Brinkmann K, Wielert U, Lauterbach H, Hochrein H, Chaplin P, Suter M, Hausmann J. ID: 78 Cytokine. 76: 79-80. DOI: 10.1016/J.Cyto.2015.08.108  0.462
2014 Wolferstätter M, Schweneker M, Späth M, Lukassen S, Klingenberg M, Brinkmann K, Wielert U, Lauterbach H, Hochrein H, Chaplin P, Suter M, Hausmann J. Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses. Journal of Virology. 88: 14396-411. PMID 25297997 DOI: 10.1128/Jvi.02082-14  0.485
2013 Lauterbach H, Pätzold J, Kassub R, Bathke B, Brinkmann K, Chaplin P, Suter M, Hochrein H. Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity. Frontiers in Immunology. 4: 251. PMID 23986761 DOI: 10.3389/Fimmu.2013.00251  0.571
2012 Oldenburg M, Krüger A, Ferstl R, Kaufmann A, Nees G, Sigmund A, Bathke B, Lauterbach H, Suter M, Dreher S, Koedel U, Akira S, Kawai T, Buer J, Wagner H, et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science (New York, N.Y.). 337: 1111-5. PMID 22821982 DOI: 10.1126/Science.1220363  0.318
2010 Lauterbach H, Bathke B, Gilles S, Traidl-Hoffmann C, Luber CA, Fejer G, Freudenberg MA, Davey GM, Vremec D, Kallies A, Wu L, Shortman K, Chaplin P, Suter M, O'Keeffe M, et al. Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. The Journal of Experimental Medicine. 207: 2703-17. PMID 20975040 DOI: 10.1084/Jem.20092720  0.391
2010 Bauer S, Bathke B, Lauterbach H, Pätzold J, Kassub R, Luber CA, Schlatter B, Hamm S, Chaplin P, Suter M, Hochrein H. A major role for TLR8 in the recognition of vaccinia viral DNA by murine pDC? Proceedings of the National Academy of Sciences of the United States of America. 107: E139; author reply E. PMID 20679190 DOI: 10.1073/Pnas.1008626107  0.38
2010 Lauterbach H, Kassub R, Pätzold J, Körner J, Brückel M, Verschoor A, Chaplin P, Suter M, Hochrein H. Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected mice. Plos One. 5: e9659. PMID 20300179 DOI: 10.1371/Journal.Pone.0009659  0.568
2010 Luber CA, Cox J, Lauterbach H, Fancke B, Selbach M, Tschopp J, Akira S, Wiegand M, Hochrein H, O'Keeffe M, Mann M. Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity. 32: 279-89. PMID 20171123 DOI: 10.1016/J.Immuni.2010.01.013  0.469
2008 Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H, Chaplin P, Suter M, O'Keeffe M, Hochrein H. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. The Journal of Clinical Investigation. 118: 1776-84. PMID 18398511 DOI: 10.1172/Jci33940  0.511
2007 Lauterbach H, Truong P, McGavern DB. Clearance of an immunosuppressive virus from the CNS coincides with immune reanimation and diversification. Virology Journal. 4: 53. PMID 17553158 DOI: 10.1186/1743-422X-4-53  0.608
2006 Lauterbach H, Zuniga EI, Truong P, Oldstone MB, McGavern DB. Adoptive immunotherapy induces CNS dendritic cell recruitment and antigen presentation during clearance of a persistent viral infection. The Journal of Experimental Medicine. 203: 1963-75. PMID 16847068 DOI: 10.1084/Jem.20060039  0.606
2006 Lauterbach H, Gruber A, Ried C, Cheminay C, Brocker T. Insufficient APC capacities of dendritic cells in gene gun-mediated DNA vaccination. Journal of Immunology (Baltimore, Md. : 1950). 176: 4600-7. PMID 16585550 DOI: 10.4049/Jimmunol.176.8.4600  0.499
2005 Lauterbach H, Ried C, Epstein AL, Marconi P, Brocker T. Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity Journal of General Virology. 86: 2401-2410. PMID 16099897 DOI: 10.1099/Vir.0.81104-0  0.496
2004 Lauterbach H, Kerksiek KM, Busch DH, Berto E, Bozac A, Mavromara P, Manservigi R, Epstein AL, Marconi P, Brocker T. Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1. Journal of Virology. 78: 4020-8. PMID 15047818 DOI: 10.1128/Jvi.78.8.4020-4028.2004  0.513
Show low-probability matches.